2024-06-10 14:55:09 ET
Summary
- Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer.
- The company's anti-inflammatory approach has received strong external validation.
- Recently, small open-label clinical trials in ALS and Alzheimer’s have shown improvement or disease stabilization.
- For the FDA, big pharma, and investors, a randomized trial is truly the big test for any drug candidate.
- Coya is considerably undervalued given the results it has shown so far.
Thesis
I consider Coya Therapeutics ( COYA ) one of several high-potential neurodegenerative plays. The company was first covered by me in May of last year. At the time, it had just announced data from two open-label clinical studies in ALS and in Alzheimer's disease [AD]. These studies were small and open-label, but consistently showed improvements or stabilization of patients treated with low-dose IL-2 [LD IL-2] or LD IL-2 + CTLA-4 Ig. Coya considers COYA 302, which is Coya's proprietary formulation of LD IL-2 and CTLA-4 Ig packaged in a combination kit, as the more promising drug candidate. COYA 302 not only promotes anti-inflammatory regulatory T cells (Tregs) but also down regulates inflammatory macrophages.
The past year, the company's progression was focused on financing, partnering and pipeline expansion....
Read the full article on Seeking Alpha
For further details see:
Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer